Inviragen is a developer of vaccines to protect against infectious diseases worldwide.
The MOU calls for the formation of a management committee co-chaired by Casey and Dan Stinchcomb, CEO of Inviragen, who will oversee the organizations’ collaborative activities.
Inviragen chief operating officer Joseph Santangelo said the scientists in the Duke-NUS Emerging Infectious Diseases Program are conducting research into viral pathogenesis and host immunology, and are pioneering methods to improve detection of emerging viral infections.